One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: A retrospective claims database analysis

Clinical Therapeutics

Volumn 33, Issue 11, 2011, Pages

  Kim, Michael H ^a   Smith, Paula J ^b   Jhaveri, Mehul ^c   Lin, Jay ^d   Klingman, David ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b IQVIA   (United States)

^c SANOFI   (France)

^d Novosys Health   (United States)

Author keywords

Amiodarone; Antiarrhythmic agents; Atrial fibrillation; Drug tolerability; Retrospective cohort study; Sotalol

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; SOTALOL;

ACUTE LIVER FAILURE; ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; BILLING AND CLAIMS; BLINDNESS; BRADYCARDIA; CHRONIC HEPATITIS; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; FIBROSING ALVEOLITIS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; OPTIC NEURITIS; PERIPHERAL NEUROPATHY; QT PROLONGATION; THYROTOXICOSIS; TORSADE DES POINTES; VISUAL IMPAIRMENT;

EID: 82855166070     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.10.005     Document Type: Article

References (44)

1. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006, 114:e257-e354.
2. Wyse D.G., Waldo A.L., DiMarco J.P., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825-1833.
3. Van Gelder I.C., Hagens V.E., Bosker H.A., et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002, 347:1834-1840.
4. Carlsson J., Miketic S., Windeler J., et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003, 41:1690-1696.
5. Gronefeld G.C., Lilienthal J., Kuck K.H., Hohnloser S.H. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. Eur Heart J 2003, 24:1430-1436.
6. Van Gelder I.C., Hemels M.E. The progressive nature of atrial fibrillation: a rationale for early restoration and maintenance of sinus rhythm. Europace 2006, 8:943-949.
7. Al-Khatib S.M., LaPointe N.M., Curtis L.H., et al. Outpatient prescribing of antiarrhythmic drugs from 1995 to 2000. Am J Cardiol 2003, 91:91-94.
8. Amiodarone hydrochloride information US Food and Drug Administration, Accessed October 31, 2011. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm118073.htm.
9. Singh B.N., Singh S.N., Reda D.J., et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005, 352:1861-1872.
10. Roy D., Talajic M., Dorian P., et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000, 342:913-920.
11. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003, 42:20-29. AFFIRM First Antiarrhythmic Drug Substudy Investigators.
12. Kochiadakis G.E., Igoumenidis N.E., Marketou M.E., et al. Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart 2000, 84:251-257.
13. Doyle J.F., Ho K.M. Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis. Mayo Clin Proc 2009, 84:234-242.
14. Vassallo P., Trohman R.G. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007, 298:1312-1322.
15. Hohnloser S.H., Kuck K.H., Lilienthal J. Rhythm or rate control in atrial fibrillation-pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000, 356:1789-1794.
16. Opolski G., Torbicki A., Kosior D.A., et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004, 126:476-486.
17. Corley S.D., Epstein A.E., DiMarco J.P., et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004, 109:1509-1513.
18. Lafuente-Lafuente C., Mouly S., Longas-Tejero M.A., et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 2006, 166:719-728.
19. Adamson D., Chang S., Hansen L.G. Health research data for the real world: the MarketScan databases. Thomson Reuters Accessed October 31, 2011. http://info.thomsonhealthcare.com/forms/HealthResearchWPRequest.
20. Anon MarketScan Studies, Abbreviated Bibliography. Thomson Reuters Accessed October 31, 2011. http://img.en25.com/Web/ThomsonReuters/2009ThomsonReutersMarketScanBibliography_0.pdf.
21. Romano P.S., Roos L.L., Jollis J.G. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993, 46:1075-1079. discussion 1081-1090.
22. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
23. Connolly S.J. Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999, 100:2025-2034.
24. Singh B.N. Amiodarone: a multifaceted antiarrhythmic drug. Curr Cardiol Rep 2006, 8:349-355.
25. Siddoway L.A. Amiodarone: guidelines for use and monitoring. Am Family Physician 2003, 68:2189-2196.
26. Betapace [prescribing information] April 2007, Bayer HealthCare Pharmaceuticals Inc, Wayne, NJ, revised.
27. Soyka L.F., Wirtz C., Spangenberg R.B. Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol 1990, 65:74A-81A. discussion 82A-83A.
28. Whitley E., Ball J. Statistics review 6: Nonparametric methods. Critical Care (London, England) 2002, 6:509-513.
29. Plackett R.L. Karl Pearson and the Chi-Squared Test. Int Statistical Review/Revue Internationale de Statistique 1983, 51:59-72.
30. Bewick V., Cheek L., Ball J. Statistics review 12: survival analysis. Critical Care (London, England) 2004, 8:389-394.
31. Krampe A., Kuhnt S. Bowker's test for symmetry and modifications within the algebraic framework. Computational Statistics Data Analysis 2007, 51:4124-4142.
32. Checkoway H., Pearce N., Kriebel D. Research Methods in Occupational Epidemiology 2004, Oxford University Press, New York, NY. 2nd ed.
33. Magro S.A., Lawrence E.C., Wheeler S.H., et al. Amiodarone pulmonary toxicity: prospective evaluation of serial pulmonary function tests. J Am Coll Cardiol 1988, 12:781-788.
34. Raebel M.A., Carroll N.M., Simon S.R., et al. Liver and thyroid monitoring in ambulatory patients prescribed amiodarone in 10 HMOs. J Manag Care Pharm 2006, 12:656-664.
35. Zimetbaum P., Ho K.K., Olshansky B., et al. Variation in the utilization of antiarrhythmic drugs in patients with new-onset atrial fibrillation. Am J Cardiol 2003, 91:81-83.
36. Camm A.J. Safety considerations in the pharmacological management of atrial fibrillation. Int J Cardiol 2008, 127:299-306.
37. Brendorp B., Pedersen O., Torp-Pedersen C., et al. A benefit-risk assessment of class III antiarrhythmic agents. Drug Saf 2002, 25:847-865.
38. Tsikouris J.P., Cox C.D. A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm. Pharmacotherapy 2001, 21:1514-1529.
39. Reiffel J.A. Drug choices in the treatment of atrial fibrillation. Am J Cardiol 2000, 85:12D-19D.
40. Marcus F.I. Risks of initiating therapy with sotalol for treatment of atrial fibrillation. J Am Coll Cardiol 1998, 32:177-180.
41. Goldschlager N., Epstein A.E., Naccarelli G.V., et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm 2007, 4:1250-1259.
42. Hohnloser S.H., Klingenheben T., Singh B.N. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994, 121:529-535.
43. Rostagno C., La Meir M., Gelsomino S., et al. Atrial fibrillation after cardiac surgery: Incidence, risk factors, and economic burden. J Cardiothorac Vasc Anesth 2010, 24:952-958.
44. Kim M.H., Klingman D., Lin J., Battleman D.S. Patterns and predictors of discontinuation of rhythm-control drug therapy in patients with newly diagnosed atrial fibrillation. Pharmacotherapy 2009, 29:1417-1426.